Clinical Trial Update: Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Imprime PGG in combination with cetuximab for recurrent or progressive KRAS wild-type colorectal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Imprime PGG

Snippet

Sponsor: HiberCell, Inc. | Conditions: Colorectal Cancer | Phase 3 | Status: TERMINATED